the apparent radiographic size of a one penny piece placed beneath the patient, thereby correcting for the variable magnification effect arising from the tubefilm distance associated with the height of the image intensifier.
Physical examination and blood tests were done within 24 hours of the admission endoscopy. Patients were then randomly allocated under doubleblind conditions, and stratifying for age, sex, and the presence or absence of either cardiovascular disease or hypertension, to take two capsules five times daily for four weeks, containing either 500 mg deglycyrrhizinised liquorice2 (DGL) Of the 29 patients on DGL in the main study, six showed healing radiologically at the end of the trial (Table 3) ; 27 were assessed gastroscopically and 14 showed healing. Similar healing rates by the respective techniques were found among the 30 patients on placebo in the main study. The extent of concordance between the gastroscopic and radiological assessment of healing is the subject of a separate paper (Bardhan et al. (in preparation) ). The median percentage change in the ulcer area was again comparable for the two treatment groups; the mean percentage change in ulcer area is shown only for comparison with previous ulcer healing studies. Among the patients not in the main study, few were assessed radiologically at the end oftherapy, but gastroscopies were done for most: the proportions healed gastroscopically were the same in those on DGL as in those on placebo.
For each treatment group, healing rates appeared to be higher for ulcers in the body and/or fundus than for other sites (Table 3 ). For the main study, combining the treatment groups, the difference among the three sites shown was not quite significant at the 5% level (X2 = 4'2 with Yates' correction; 2 df), while the difference between the body and/or fundus compared with the other two sites combined was significant at this level (X2 = 4'7; 1 df). Similar conclusions obtain if the data for all 95 patients for whom the site was known are used. No. with missing data (1)
(-) (-) (3)
Antacid mixture (ml): Mean  178  242  114  198  153  222  SD  152  219  112  201  139  212 No. with missing data (2)
(-) (-)
(8) Total no. ofpatients gain was only 03 kg. The same patient had previously become oedematous while taking carbenoxolone sodium. With this exception, no abnormality occurred in any of the biochemical and haematological indices measured; in particular, hypokalaemia was not recorded.
Discussion
Previously published trials of DGL have used radiological criteria alone in determining ulcer healing. In this trial both methods of assessment agreed in their failure to demonstrate therapeutic benefit, although there was substantial disagreement in their assessment of ulcer healing in individual cases. Treatment and placebo groups were similar in all respects that might be expected to influence healing, most particularly in smoking habits. Engqvist et al. (1973) have suggested that ulcers at the angulus heal less well than those at other sites. Our results show poorer healing of ulcers either at or distal to the angulus, but it is clear from Table 4 that there is no difference in healing rates between the treatment groups, even when the site of ulcer is taken into account.
The previous trials claiming benefit need careful scrutiny to explain their different conclusion. The two trials reported in 1968 are inadequate in size and in data on comparability (Table 1) . The placebo group of Turpie et al. (1969) is remarkable as only one of 17 ulcers healed, and the advantage of DGL in the trial of Montgomery and Cookson (1972) was not statistically significant. None refers to how ulcers which increase in size were dealt with.
All DGL used in our own and previous trials was prepared by the same manufacturer and, although in all other trials the DGL was in the form of Caved-S, a preparation which also contains bismuth subnitrate and other antacids, we think it unlikely that any difference in formulation explains the apparent therapeutic failure in the present trial.
Can we firmly conclude that deglycyrrhizinised liquorice has no therapeutic activity? This trial was designed to be capable of detecting a doubling of the assumed placebo healing rate of around 30%. Between 40 and 45 patients per treatment group were required to have only 20% chance of failing to detect any such doubling of healing rate, which would be significant at the 5% level (Clark and Downie, 1966) ; to reduce to 5% the chance of failing to detect it around 70 patients per treatment group would be required. The total study here had 48 patients per treatmentgroup anditis therefore unlikely that DGL produces the doubling of the placebo healing rate which would justify its continuing place in clinical practice.
liquorice in gastric ulcer. 
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